百亿级私募入场“扫货” 加码创新药与互联网ETF

Core Insights - The report highlights the increasing interest of billion-level private equity firms in ETFs and LOFs, particularly in the internet and innovative pharmaceutical sectors as of the end of 2024 [1][2]. Group 1: Investment Trends - A total of 16 billion-level private equity firms appeared in the top ten shareholders of public funds by the end of 2024, with a significant focus on internet and innovative pharmaceutical sectors [1]. - Notably, heavyweights like Rongyang Investment and Ningquan Asset have increased their holdings in healthcare ETFs, indicating a strategic shift towards these sectors [2][3]. - The innovative pharmaceutical sector is expected to experience a turning point this year, driven by favorable healthcare policies and the global competitiveness of Chinese innovative drug companies [2]. Group 2: Sector Focus - The internet sector is a key area of investment for billion-level private equity firms, with a notable shift towards Hong Kong stocks, particularly those related to the Hang Seng Technology Index [3]. - Many top private equity firms are reducing exposure to overheated sectors like robotics while increasing their positions in internet-related assets [3]. Group 3: ETF Utilization - ETFs have become an important tool for private equity firms to allocate assets flexibly, including bonds and overseas assets, amidst China's economic transformation [4][5]. - High-profile fund managers are increasingly using ETFs to manage risks and adapt to market changes, indicating a growing trend towards diversified index funds [5].